Teleflex (NYSE:TFX) Raised to “Buy” at StockNews.com

Teleflex (NYSE:TFX) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Thursday.

A number of other brokerages have also commented on TFX. Stephens boosted their price target on shares of Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Mizuho decreased their price target on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a research note on Friday, November 1st. Truist Financial restated a “hold” rating and set a $227.00 price target (down previously from $255.00) on shares of Teleflex in a research note on Monday, November 4th. Finally, Royal Bank of Canada decreased their price target on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Teleflex has an average rating of “Moderate Buy” and an average target price of $259.25.

Teleflex Stock Up 0.5 %

Teleflex stock opened at $192.00 on Thursday. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. Teleflex has a 12-month low of $185.66 and a 12-month high of $257.85. The firm’s fifty day moving average is $221.96 and its 200 day moving average is $222.66. The company has a market capitalization of $8.92 billion, a PE ratio of 38.17, a PEG ratio of 1.99 and a beta of 1.18.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, October 31st. The medical technology company reported $3.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.38 by $0.11. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The company had revenue of $764.40 million for the quarter, compared to the consensus estimate of $768.68 million. During the same quarter in the previous year, the company earned $3.64 EPS. Teleflex’s quarterly revenue was up 2.4% compared to the same quarter last year. As a group, sell-side analysts predict that Teleflex will post 13.98 EPS for the current fiscal year.

Institutional Trading of Teleflex

Several institutional investors have recently made changes to their positions in the company. Oregon Public Employees Retirement Fund grew its stake in shares of Teleflex by 1.2% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,021 shares of the medical technology company’s stock worth $846,000 after acquiring an additional 46 shares in the last quarter. Cromwell Holdings LLC grew its position in Teleflex by 59.0% during the third quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock valued at $33,000 after buying an additional 49 shares during the period. Crossmark Global Holdings Inc. grew its position in Teleflex by 1.9% during the second quarter. Crossmark Global Holdings Inc. now owns 2,779 shares of the medical technology company’s stock valued at $584,000 after buying an additional 53 shares during the period. Apollon Wealth Management LLC grew its position in Teleflex by 3.7% during the third quarter. Apollon Wealth Management LLC now owns 1,524 shares of the medical technology company’s stock valued at $377,000 after buying an additional 55 shares during the period. Finally, SRS Capital Advisors Inc. grew its position in Teleflex by 0.3% during the third quarter. SRS Capital Advisors Inc. now owns 19,587 shares of the medical technology company’s stock valued at $4,844,000 after buying an additional 60 shares during the period. Institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.